{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T06:13:04Z","timestamp":1696918384826},"reference-count":73,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Paediatric HIV treatment must address various special considerations. Administration of pharmacokinetically enhanced protease inhibitors (PIs) can improve paediatric therapeutic outcomes. The objective of this study was to review the use of boosted PI regimens in children.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Systematic literature searches of published manuscripts and conference databases using generic drug names and specific keywords were performed to ensure thorough and balanced reporting of available data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Boosted PI regimens offer multiple options across a range of ages and are efficacious in na\u00efve and experienced children; safety and tolerability are similar to those observed in adults. Novel boosted PI simplification approaches may foster adherence and diminish resistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Boosted PIs are key components of first\u2010 and second\u2010line treatments in children. Identifying factors associated with the response to highly active antiretroviral therapy in children may ultimately permit individualized therapies.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2009.00728.x","type":"journal-article","created":{"date-parts":[[2009,7,2]],"date-time":"2009-07-02T02:25:47Z","timestamp":1246501547000},"page":"536-547","source":"Crossref","is-referenced-by-count":7,"title":["Boosted protease inhibitors as a therapeutic option in the treatment of HIV\u2010infected children"],"prefix":"10.1111","volume":"10","author":[{"given":"JT","family":"Ramos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,22]]},"reference":[{"key":"e_1_2_4_2_2","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS).2008Report on the global AIDS epidemic [UNAIDS web site]. Geneva UNAIDS. Available athttp:\/\/viewer.zmags.com\/showmag.php?mid=ghsqd(accessed 11 August 2008)."},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_4_4_2","unstructured":"WHO Technical Reference Group and Paediatric HIV\/ART Care Guideline Group.2008. WHO antiretroviral therapy for infants and children [WHO web site]. World Health Organization. Available athttp:\/\/www.who.int\/hiv\/pub\/paediatric\/WHO_Paediatric_ART_guideline_rev_mreport_2008.pdf(accessed 28 October 2008)."},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411033311801"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011157"},{"key":"e_1_2_4_7_2","first-page":"1236","article-title":"Mortality of infected and uninfected infants born to HIV\u2010infected mothers in Africa","volume":"364","author":"Newell ML","year":"2004","journal-title":"a pooled analysis"},{"key":"e_1_2_4_8_2","unstructured":"ViolariA CottonM GibbDet al.2007. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV\u2010infected infants: evidence from the children with HIV early antiretroviral therapy (CHER) study.4th IAS Conference on HIV Pathogenesis. Sydney Australia July 2007 [Abstract WESS103]."},{"key":"e_1_2_4_9_2","unstructured":"The working group on antiretroviral therapy and medical management of HIV\u2010infected children and National Institutes of Health.2008. Guidelines for the use of antiretroviral agents in pediatric HIV infection [NIH web site]. National Institutes of Health. Available athttp:\/\/www.aidsinfo.nih.gov\/ContentFiles\/pediatricGuidelines.pdf(accessed 28 October 2008)."},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2004.00227.x"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31817acf7b"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/427192"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012354"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/380509"},{"key":"e_1_2_4_15_2","volume-title":"Kaletra (lopinavir\/ritonavir) Prescribing Information","author":"Abbott Laboratories.","year":"2008"},{"key":"e_1_2_4_16_2","volume-title":"Lexiva (fosamprenavir\/calcium) Full Prescribing Information","author":"GlaxoSmithKline.","year":"2008"},{"key":"e_1_2_4_17_2","volume-title":"Reyetaz (atazanavir sulfate) Full Prescribing Information","author":"Bristol\u2010Myers Squibb.","year":"2008"},{"key":"e_1_2_4_18_2","volume-title":"Aptivus (tipranavir) Full Prescribing Information","author":"Boehringer Ingelheim.","year":"2008"},{"key":"e_1_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000247140.94669.1b"},{"key":"e_1_2_4_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-007-6068-1"},{"key":"e_1_2_4_21_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.3.3.347"},{"key":"e_1_2_4_22_2","unstructured":"BolognaR RuginaS CahnPet al.2008. Safety and efficacy of darunavir co\u2010administered with low\u2010dose ritonavir in treatment\u2010experienced children and adolescents at week 24.15th Conference on Retroviruses and Opportunistic Infections. Boston MA February 2008 [Abstract 78LB]."},{"key":"e_1_2_4_23_2","unstructured":"SekerV Van De CasteeleT Van BaelenBet al.2008. Dose selection and pharmacokinetics\u2010pharmacodynamics (PK\u2010PD) of darunavir coadministered with low\u2010dose ritonavir (DRV\/r) in the DELPHI (TMC114\u2010C212) Trial in treatment\u2010experienced HIV\u20101\u2010infected children and adolescents.17th International AIDS Conference. Mexico City Mexico August 2008 [Abstract TUPE0078]."},{"key":"e_1_2_4_24_2","volume-title":"Prezista (darunavir) Prescribing Information","author":"Tibotec Therapeutics.","year":"2008"},{"key":"e_1_2_4_25_2","first-page":"1183","article-title":"Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997\u20132005","volume":"332","author":"Menson EN","year":"2006","journal-title":"cohort study"},{"key":"e_1_2_4_26_2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/01.inf.0000055061.97567.34","article-title":"Forty\u2010eight\u2010week evaluation of lopinavir\/ritonavir, a new protease inhibitor, in human immunodeficiency virus\u2010infected children","volume":"22","author":"S\u00e1ez LX","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"e_1_2_4_27_2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/135965350701200405","article-title":"Plasma concentrations of the HIV\u2010protease inhibitor lopinavir are suboptimal in children aged 2 years and below","volume":"12","author":"Verweel G","year":"2007","journal-title":"Antivir Ther"},{"key":"e_1_2_4_28_2","first-page":"249","article-title":"Pharmacokinetics, safety and efficacy of lopinavir\/ritonavir in infants less than 6 months of age","volume":"22","author":"Chadwick EG","year":"2008","journal-title":"24 week results"},{"key":"e_1_2_4_29_2","unstructured":"CapparelliE PintoJA RobbinsBet al.2008. Lopinavir pharmacokinetic maturational changes and variability in HIV\u2010infected infants beginning kaletra therapy at <6 weeks of age.15th Conference on Retroviruses and Opportunistic Infections. Boston MA February 2008 [Abstract 573]."},{"key":"e_1_2_4_30_2","unstructured":"KleinCE ChiuY\u2010L CausemakerSKet al.2007. Lopinavir\/ritonavir (LPV\/r) 100\/25 mg tablet developed for pediatric use: bioequivalence to the LPV\/r 200\/50 mg tablet at a dose of 400\/100 mg and predicted dosing regimens in children.11th European AIDS Conference. Madrid Spain October 2007 [Abstract P4.1\/01]."},{"key":"e_1_2_4_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.336-341.2005"},{"key":"e_1_2_4_32_2","unstructured":"KiserJJ RutsteinR AldrovandiGet al.2008. Pharmacokinetics of atazanavir\/ritonavir in HIV\u2010infected infants children and adolescents: PACTG 1020A.15th Conference on Retroviruses and Opportunistic Infections. Boston MA February 2008 [Abstract 767]."},{"key":"e_1_2_4_33_2","unstructured":"SaboJ CahnP Della NegraMet al.2008. Population pharmacokinetic assessment of systemic steady\u2010state tipranavir concentrations for HIV\u2010positive pediatric patients administered tipranavir\/ritonavir: Bl 1182.14 and PACTG 1051 Study Team.13th Conference on Retroviruses and Opportunistic Infections. Denver CO February 2006 [Abstract 687]."},{"key":"e_1_2_4_34_2","unstructured":"SungkanuparphS ApiwattanakulN ThititanyanontA ChantratitaW SirinavinS.2008. HIV\u20101 drug resistance mutations in children failing an initial NRTI\u2010based regimen and options for a second\u2010line antiretroviral regimen.15th Conference on Retroviruses and Opportunistic Infections. Boston MA February 2008 [Abstract 588]."},{"key":"e_1_2_4_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000180578.38584.da"},{"key":"e_1_2_4_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00224-08"},{"key":"e_1_2_4_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31816b4539"},{"key":"e_1_2_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(02)00183-4"},{"key":"e_1_2_4_39_2","unstructured":"CahnP RenzC Saez\u2010LlorensXet al.2001. Kaletra\u2122(ABT\u2010378\/ritonavir) in HIV\u2010infected children at 72 weeks.1st International AIDS Conference on HIV Pathogenesis and Treatment. Buenos Aires Argentina July 2001 [Abstract 779]."},{"key":"e_1_2_4_40_2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/135965350601100412","article-title":"Pharmacokinetics of a once\u2010daily regimen of lopinavir\/ritonavir in HIV\u20101\u2010infected children","volume":"11","author":"Van Der Lee M","year":"2006","journal-title":"Antivir Ther"},{"key":"e_1_2_4_41_2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/01.inf.0000055061.97567.34","article-title":"Forty\u2010eight\u2010week evaluation of lopinavir\/ritonavir, a new protease inhibitor, in human immunodeficiency virus\u2010infected children","volume":"22","author":"Saez\u2010Llorens X","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"e_1_2_4_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181646d5a"},{"key":"e_1_2_4_43_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540701203493"},{"key":"e_1_2_4_44_2","unstructured":"CunninghamC FreedmanA ReadSet al.2007. Safety and antiviral activity of fosamprenavir\u2010containing regimens in HIV\u2010infected 2\u2010 to 18\u2010year\u2010old pediatric subjects (Interim data Study APV29005).14th Conference on Retroviruses and Opportunistic Infections. Los Angeles CA February 2007 [Abstract 718]."},{"key":"e_1_2_4_45_2","unstructured":"ChadwickE BorkowskyW FortunyCet al.2007. Safety and antiviral activity of fosamprenavir\/ritonavir once\u2010daily regimens in HIV\u2010infected pediatric subjects ages 2 to 18 years (48\u2010Week Interim data Study APV20003).14th Conference on Retroviruses and Opportunistic Infections. Los Angeles CA February 2007 [Abstract 719]."},{"key":"e_1_2_4_46_2","unstructured":"RutsteinR SamsonP KiserJJet al.2007. The PACTG 1020A protocol: atazanavir with or without ritonavir in HIV\u2010infected infants children and adolescents.14th Conference on Retroviruses and Opportunistic Infections. Los Angeles CA February 2007 [Abstract 715]."},{"key":"e_1_2_4_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830c481b"},{"key":"e_1_2_4_48_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200828060-00005"},{"key":"e_1_2_4_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000142170.52155.7f"},{"key":"e_1_2_4_50_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-2802"},{"key":"e_1_2_4_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki469"},{"key":"e_1_2_4_52_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2005.21.398"},{"key":"e_1_2_4_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm436"},{"key":"e_1_2_4_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000180574.18804.90"},{"key":"e_1_2_4_55_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000137408.78031.37"},{"key":"e_1_2_4_56_2","unstructured":"MathurM HandelsmanE TizerK DesaiN.2002. 1 year follow up of salvage therapy (ST) with lopinavir\/ritonavir and amprenavir based combinations in children failing previous highly active antiretroviral therapy (HAART) regimens.14th International AIDS Conference. Barcelona Spain July 2002 [Abstract TuPeB4626]."},{"key":"e_1_2_4_57_2","unstructured":"RamosJ GarcaL RojoPet al.2003. High prevalence of metabolic abnormalities in HIV\u2010infected children treated with HAART.10th Conference on Retroviruses and Opportunistic Infections. Boston MA February 2003 [Abstract 772]."},{"key":"e_1_2_4_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181648e16"},{"key":"e_1_2_4_59_2","unstructured":"SamsonP RutsteinR FentonTet al.2006. Changes in cholesterol and triglyceride levels among pediatric patients treated with atazanavir with or without ritonavir boosting: the 1020A NIH PACTG protocol.13th Conference on Retroviruses and Opportunistic Infections. Denver CO February 2006 [Abstract 689]."},{"key":"e_1_2_4_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200409030-00004"},{"key":"e_1_2_4_61_2","first-page":"1208","article-title":"Long\u2010term observation of adolescents initiating HAART therapy","volume":"23","author":"Flynn PM","year":"2007","journal-title":"three-year follow-up"},{"key":"e_1_2_4_62_2","first-page":"e416","article-title":"Long\u2010term safety and efficacy of a once\u2010daily regimen of emtricitabine, didanosine, and efavirenz in HIV\u2010infected, therapy\u2010na\u00efve children and adolescents","volume":"120","author":"McKinney RE","year":"2007","journal-title":"Pediatric AIDS Clinical Trials Group Protocol P1021"},{"key":"e_1_2_4_63_2","first-page":"239","article-title":"Plasma pharmacokinetics of once\u2010 vs. twice\u2010daily lamivudine and abacavir","volume":"10","author":"Bergshoeff A","year":"2005","journal-title":"simplification of combination treatment in HIV-1-infected children (PENTA-13)"},{"key":"e_1_2_4_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl136"},{"key":"e_1_2_4_65_2","doi-asserted-by":"crossref","unstructured":"VerweelG Van der LeeM BurgerD De GrootR.2005. 6\u2010month follow\u2010up of once\u2010daily lopinavir\/ritonavir in HIV\u20101\u2010infected children.12th Conference on Retroviruses and Opportunistic Infections. Boston MA February 2005 [Abstract 769].","DOI":"10.1310\/EYBU-95QU-J9JM-JC1E"},{"key":"e_1_2_4_66_2","unstructured":"BurgerD Van der FlierM VerweelGet al.2007. Pharmacokinetics of lopinavir in HIV\u20101\u2010infected children taking the new tablet formulation once\u2010daily.11th European AIDS Conference. Madrid Spain October 2007 [Abstract P15.2\/03]."},{"key":"e_1_2_4_67_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000234069.37972.94"},{"key":"e_1_2_4_68_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200501010-00009"},{"key":"e_1_2_4_69_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/135965350400900211","article-title":"Safety and efficacy of a NRTI\u2010sparing HAART regimen of efavirenz and lopinavir\/ritonavir in HIV\u20101\u2010infected children","volume":"9","author":"Fraaij PL","year":"2004","journal-title":"Antivir Ther"},{"key":"e_1_2_4_70_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f4243b"},{"key":"e_1_2_4_71_2","first-page":"777","article-title":"The Monark Trial","volume":"22","author":"Hill A","year":"2008","journal-title":"where now for boosted protease inhibitor monotherapy?"},{"key":"e_1_2_4_72_2","doi-asserted-by":"publisher","DOI":"10.1086\/589622"},{"key":"e_1_2_4_73_2","unstructured":"LowenthalE MarapeM MathubaKet al.2006. A randomized comparative trial of continuousvs. intermittent HAART in HIV\u2010infected infants and children in Botswana.13th Conference on Retroviruses and Opportunistic Infections. Denver CO February 2006 [Abstract 700]."},{"key":"e_1_2_4_74_2","unstructured":"PrendergastA ChoncoF Tudor\u2010WilliamsGet al.2008. Randomized controlled trial of 3 approaches to management of HIV\u2010infected infants.15th Conference on Retroviruses and Opportunistic Infections. Boston MA February 2008 [Abstract 77LB]."}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00728.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00728.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T16:57:17Z","timestamp":1696870637000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00728.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,22]]},"references-count":73,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00728.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00728.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,22]]}}}